Ergotamine is a vasoconstrictive alkaloid derived from the ergot fungus, primarily used for the acute treatment of migraine attacks. Developed in the early 20th century, it works by stimulating serotonin (5-HT1) receptors in cranial blood vessels, leading to constriction of dilated intracranial arteriesand relief of migraine pain. Ergotamine is usually administered orally, sublingually, or by suppository, and its use is limited by potentialvascular side effects, including peripheral ischemia and hypertension. Because of these risks, ergotamine is reserved for acute migraine episodes and is generally avoided in patients with cardiovascular disease, uncontrolled hypertension, or pregnancy.
BRAND NAMES
Cafergot – combination of ergotamine and caffeine, commonly used for acute migraine attacks
Ergomar – sublingual tablets for rapid migraine relief.
MECHANISM OF ACTION
Ergotamine is an ergot alkaloid that acts as a partial agonist at serotonin 5-HT₁B and 5-HT₁D receptors in cranial blood vessels. Activation of these receptors leads to constriction of dilated intracranial arteries and inhibition of neuropeptide release from trigeminal nerve endings, which reduces neurogenic inflammation associated with migraines.
PHARMACOKINETICS
Absorption
Ergotamine is partially absorbed after oral administration, with variable bioavailability due to significant first-pass hepatic metabolism. Peak plasma concentrations are typically reached within 30 minutes to 2 hours after sublingual or oral dosing.
Distribution
Ergotamine has a moderate volume of distribution, approximately 3–5 L/kg, reflecting its extensive tissue binding and high plasma protein affinity.
Metabolism
Ergotamine is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme CYP3A4. It undergoes oxidative metabolism to several inactive metabolites, which reduces the amount of active drug reaching systemic circulation.
Elimination
Ergotamine and its metabolites are primarily excreted via the bile into the feces, with only a small fraction eliminated in the urine. Its elimination half-life is approximately 2–3 hours, but clinical effects can persist longer due to active metabolites and tissue binding.
PHARMACODYNAMICS
Ergotamine exerts its therapeutic effects by vasoconstricting dilated cranial and meningeal blood vessels through partial agonism at serotonin 5-HT₁B and 5-HT₁D receptors. This action reduces neurogenic inflammation by inhibiting the release of vasoactive neuropeptides from trigeminal nerve endings, which are implicated in migraine pathophysiology. Additionally, ergotamine has adrenergic and dopaminergic activity, contributing to peripheral vasoconstriction and central modulation of pain pathways. The combined effect alleviates migraine pain, throbbing, and associated symptoms such as nausea, photophobia, and phonophobia.
ADMINISTRATION
Ergotamine is administered via oral, sublingual, or rectal routes depending on the formulation and patient needs. Oral tablets are often combined with caffeine to enhance absorption and are taken at the onset of a migraine attack.
DOSAGE AND STRENGTH
Ergotamine is available in oral, sublingual, and rectal formulations, often combined with caffeine to improve absorption. Oral tablets typically contain 1 mg of ergotamine per tablet, with a maximum dose of 6 mg per migraine attack and 10 mg per week.
DRUG INTERACTIONS
Ergotamine interacts with several medications primarily due to its vasoconstrictive properties and metabolism by CYP3A4 enzymes. Concomitant use with CYP3A4 inhibitors, such as ketoconazole, erythromycin, or HIV protease inhibitors, can greatly increase plasma ergotamine levels, leading to severe vasospasm, ischemia, or ergotism.
FOOD INTERACTIONS
Ergotamine absorption can be affected by food intake, as a high-fat meal may delay gastric emptying and slow the onset of action. For optimal efficacy, ergotamine is often recommended to be taken on an empty stomach or with a light meal, especially in oral or sublingual forms, to ensure rapid relief of migraine symptoms.
CONTRAINDICATIONS
Ergotamine is contraindicated in patients with a known hypersensitivity to ergot alkaloids, as exposure may trigger severe allergic reactions. It should not be used in individuals with peripheral vascular disease, coronary artery disease, or uncontrolled hypertension, due to the risk of excessive vasoconstriction and cardiovascular complications.
SIDE EFFECTS
Nausea and vomiting – common, often dose-related
Abdominal pain – gastrointestinal discomfort
Dizziness or vertigo – due to vasoconstriction
Peripheral vasospasm – cold hands and feet, numbness
Chest pain or angina – especially in patients with cardiovascular disease
Hypertension – transient or sustained increase in blood pressure
Tingling or paresthesia – in extremities.
TOXICITY
Ergotamine toxicity, often referred to as ergotism, occurs with overdose or prolonged use, particularly when combined with CYP3A4 inhibitors. Toxicity manifests as severe and prolonged vasoconstriction, leading to peripheral ischemia, cold and numb extremities, tingling, and in extreme cases, gangrene.
